Luigi De Cicco

Luigi De Cicco

Auto-generated profile, based on publicly available information

Luigi De Cicco

Division of Radiotherapy, European Institute of Oncology, Milan, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2010 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
AVAndrea Vavassori
Andrea Vavassori
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
GBGiancarlo Beltramo
Giancarlo Beltramo
LCLuigi De Cicco
Luigi De Cicco
LFLaura Fariselli
Laura Fariselli
RORoberto Orecchia
Roberto Orecchia
Aims and background: Technological advances in treatment planning and execution are providing new potential opportunities in the treatment of recurrent prostate cancer. This study was conducted to evaluate the feasibility and safety of reirradiation with image-guided radiosurgery using CyberKnife, a robotic arm-driven compact linear accelerator, for intraprostatic recurrence after external beam radiotherapy (EBRT). Methods: Between September 2007 and May 2008, 6 patients diagnosed with locally recurrent prostate cancer after EBRT were treated using the CyberKnife system. The total reirradiation dose was 30 Gy in five fractions. Prior to radiosurgery four patients were treated with androgen-deprivation therapy. Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and the Houston-Phoenix definition (PSA nadir + 2 ng/mL) were used for toxicity and biochemical failure evaluation, respectively. Results: After a median follow-up of 11.2 months (range, 9.6–18.6 months), all patients are alive with no evidence of severe urinary or rectal acute morbidity. Local control cannot be exactly determined due to the short follow-up and the bias of the use of androgen ablation. Four patients had biochemical failure, three of them with clinical failure evidence (lymph node, bone and lung metastasis, respectively): none of these patients had clinical evidence of tumor persistence in the prostate. Conclusions: Salvage radiosurgery with CyberKnife after irradiation is feasible with low urinary and rectal morbidity. A longer follow-up and a larger number of patients are necessary to evaluate its effectiveness and optimal patient selection criteria.

1 September 2014 in Brachytherapy
Verified
Journal Article
Closed access
LCLuigi De Cicco
Luigi De Cicco
BVBarbara Vischioni
Barbara Vischioni
AVAndrea Vavassori
Andrea Vavassori
FGFederica Gherardi
Federica Gherardi
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
RORoberto Orecchia
Roberto Orecchia

7 December 2009 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
LCLuigi De Cicco
Luigi De Cicco
LCLaura Cella
Laura Cella
RLRaffaele Liuzzi
Raffaele Liuzzi
RSRaffaele Solla
Raffaele Solla
AFAntonio Farella
Antonio Farella
RPRoberto Pacelli
Roberto Pacelli
Background: Primary orbital lymphoma is a rare disease that accounts for 10% of all orbital tumors. Radiotherapy on the orbital cavity is the treatment of choice for this unusual presentation of localized non-Hodgkin's lymphoma (NHL). The aim of this study is to retrospectively evaluate the effectiveness and the toxicity of radiation treatment in patients with primary orbital lymphoma. Methods: Forty-seven consecutive patients having primary orbital lymphoma treated in our department between May 1983 and September 2006 were investigated in a retrospective study. Either 60Co γ rays or 6 MV X rays were used to deliver daily fractions of 1.8 or 2.0 Gy, 5 times/week, with total doses ranging from 34.2 to 50 Gy. Forty-three patients had stage IE, three had stage II and one stage IV disease. Thirty-eight patients had marginal zone B-cell lymphoma, 5 diffuse large B cell lymphoma, 3 mantle cell lymphoma and 1 Burkitt lymphoma. Local control (LC), disease free survival (DFS), overall survival (OS) and late side effects were evaluated in all patients. Results: With a median follow up of 45 months, LC was obtained in 100% of patients. The estimated 5- and 7-year DFS rates were 75.8% and 55.3%, and the 5- and 7-year OS rates were 88.7% and 79.9% respectively. Acute toxicity was minimal. Late toxicity such as cataract, keratitis, retinopathy and xerophthalmia occurred respectively in 12 (25.5%), 5 (10.6%), 1 (2.1%), and 9 (19.1%) patients. Conclusion: Radiotherapy is an effective and at the same time well tolerated treatment for primary orbital lymphoma.

1 September 2008 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
LCLuigi De Cicco
Luigi De Cicco
AVAndrea Vavassori
Andrea Vavassori
BJBarbara A Jereczek-Fossa
Barbara A Jereczek-Fossa
GPGiancarlo Pruneri
Giancarlo Pruneri
GCGianpiero Catalano
Gianpiero Catalano
RORoberto Orecchia
Roberto Orecchia
Merkel cell carcinoma (MCC) is an uncommon aggressive neuroendocrine skin carcinoma. It usually affects sun-exposed skin of white elderly people. MCC is characterized by a high incidence of early locoregional relapse and distant metastases. Because of its rarity and the resulting lack of prospective randomized trials, data regarding the optimal treatment of MCC are limited. Despite aggressive multimodality treatment, the prognosis of patients bearing MCC is often poor. We report three cases of lymph node metastases of MCC with unknown primary sites. Two patients died 17 and 28 months after diagnosis due to brain and pancreatic metastases, respectively, without evidence of cutaneous disease. The third patient is alive and free of tumor at 16 months from the diagnosis. After an accurate diagnosis of lymph node metastases from MCC, the absence of a primary tumor at complete initial evaluation and during adequate follow-up can confirm this particular clinical scenario. The prognosis seems to be analogous to that of cases with similar disease stage (lymph node involvement) but a known primary site.

15 December 2018 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
AOAiro-L) The Lombardy Section Of The Italian Society Of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia
Airo-L) The Lombardy Section Of The Italian Society Of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia
BJBarbara Alicja Jereczek-Fossa
Barbara Alicja Jereczek-Fossa
BBBarbara Bortolato
Barbara Bortolato
MGMarianna Alessandra Gerardi
Marianna Alessandra Gerardi
SDSamantha Dicuonzo
Samantha Dicuonzo
PAPaolo Antognoni
Paolo Antognoni

25 October 2018 in La radiologia medica
Verified
Journal Article
Closed access
PDF file
LCLuigi De Cicco
Luigi De Cicco
SBStefano Bracelli
Stefano Bracelli